SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-14-034018
Filing Date
2014-02-04
Accepted
2014-02-04 08:37:36
Documents
10
Period of Report
2014-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d667914d8k.htm 8-K 28481
2 EX-1.1 d667914dex11.htm EX-1.1 122618
3 EX-1.2 d667914dex12.htm EX-1.2 5014
4 EX-4.1 d667914dex41.htm EX-4.1 73323
5 EX-4.2 d667914dex42.htm EX-4.2 136127
6 EX-5.1 d667914dex51.htm EX-5.1 9010
7 EX-99.1 d667914dex991.htm EX-99.1 6855
8 EX-99.2 d667914dex992.htm EX-99.2 8242
9 GRAPHIC g667914g48l65.jpg GRAPHIC 4683
10 GRAPHIC g667914g91y96.jpg GRAPHIC 6265
  Complete submission text file 0001193125-14-034018.txt   406382
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 14570146
SIC: 2835 In Vitro & In Vivo Diagnostic Substances